medigraphic.com
ISSN 2448-8909 (Impreso)

2000, Número 2

<< Anterior Siguiente >>

Med Crit 2000; 14 (2)


Manejo farmacológico de la insuficiencia cardiaca en la terapia intensiva pediátrica

Millán JC, Lizalde IML, Torres VA

Idioma: Español
Referencias bibliográficas: 52
Paginas: 60-66
Archivo PDF: 160.59 Kb.


RESUMEN

Objetivo: Evaluar el tratamiento farmacológico de la insuficiencia cardiaca (IC) en una unidad de cuidados intensivos pediátricos (UCIP).
Diseño: Estudio prospectivo y obervacional.
Lugar: Una UCIP de un hospital general de la Ciudad de México.
Pacientes: Se evaluaron todos los pacientes con IC ingresados a la UCIP durante un año.
Intervenciones: Ninguna.
Resultados: Ingresaron 50 pacientes con IC a la UCIP.De estos pacientes 12% recibieron dobutamina, 38% dobutamina/dopamina, 22% noradrenalina, 10% adrenalina, 10% amrinona y 8% vasodilatadores.
Conclusión: La dobutamina es el fármaco más utilizado en el manejo de la IC de los pacientes críticos en nuestro hospital


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Kaplan S. New drugs approaches to the treatment of heart failure in infants and children. Drugs 1990;39(3):388-393.

  2. Feltes TF. Cardiovascular physiology in the Pediatric Intensive Care Unit. In: Pediatric Critical Care Clinical Review Series Part I. Society of Critical Care Medicine 1992;23-25:1-16.

  3. Notterman DA. Cardiovascular pharmacology in the Pediatric Intensive Care Unit. In: Pediatric Critical Care Clinical Review Series Part I. Society of Critical Care Medicine 1992;23-25:83-114.

  4. Wessel DL. Postoperative management of the open heart surgery patient. In: Pediatric Critical Care Clinical Review Series Part I. Society of Critical Care Medicine 1992;23-25:135-154.

  5. Opie LH. Drugs for the heart. Saunders Company, USA. Third edition 1992.

  6. Deedwania PC, Crawford MH et al. Consideraciones actuales sobre insuficiencia cardiaca congestiva. Clínicas Cardiológicas de Norteamérica 1994;1:31-152.

  7. Bell SG. Neonatal cardiovascular pharmacology. Neonatal Network 1998;17(2):7-15.

  8. Leier CV, Dei Cas L, Metra M. Clinical relevance and management of the major electrolyte abnormalities in congestive heart failure; hyponatremia, hypokalemia and hypomagnesemia. Am Heart J 1994;128(3):564-74.

  9. Kleber FX, Wensel R. Current guidelines for the treatment of congestive heart failure. Drugs 1996;51(1):89-98.

  10. Bonarjee V, Dickstein K. Novel drugs and current therapeutic approaches in the treatment of heart failure. Drugs 1996;51(3):347-58.

  11. Gheorghiade M, Benatar D, Konstam MA et al. Pharmacotherapy for systolic dysfunction: a review of randomized clinical trials. Am J Cardiol 1997;80(8B):14H-27H.

  12. Murphy MR, Elliot WJ. Dopamine and dopamine receptor agonists in cardiovascular therapy. Critical Care Med 1990;18(1):S14-S17.

  13. Dechan SC, Grant IS. Haemodynamic changes in neurogenic pulmonary edema: effect of dobutamine. Intensive Care Med 1996;22:672-76.

  14. Berré J, De Backer D, Moraine JJ et al. Dobutamine increases cerebral blood flow velocity and jugular bulb hemoglobin saturation in septic shock. Crit Care Med 1997;25(3):392-98.

  15. Schwenzer KJ, Kopel RF. Hemodynamic and metabolic effects of dobutamine in 18 patients after open heart surgery. Crit Care Med 1990;18(10):1107-1110.

  16. Rosseel PM, Santman EW, Bouter H, Dott CS. Postcardiac surgery low cardiac output syndrome: dopexamine or dopamine? Intensive Care Med 1997;23:962-68.

  17. Vogt J, Reinelt H, Radermacher P. Dobutamine and the oxygen uptake/supply relationship in sepsis: from global to regional-nothing is simple and easy. Intensive Care Med 1997;23:715-17.

  18. Svedjeholm R, Hallhagen S, Ekrtoh R et al. Dopamine and high dose Insulin Infusion after a cardiac operation: effects on myocardial metabolism. Ann Thorac Surg 1991;31:262-70.

  19. Indolfi C, Piscione F, Perrone-Filardi P et al. Inotropic stimulation by dobutamine increases left ventricular regional function at the expense of metabolism in hibernating myocardium. Am Heart J 1996;132:542-49.

  20. Klocke RK, Mager G, Kux A et al. Effects of a twenty four hour milrinone infusion in patients with severe heart failure and cardiogenic shock as a function of the hemodynamic initial condition. Am Heart J 1991;121 Suppl:1965-73.

  21. Packer M, Carver JR, Rodeheffer RJ et al. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 1991;325:1468-75.

  22. Mehra MR, Ventura HO, Kapoor Ch et al. Safety and clinical utility of long term intravenous milrinone in advanced heart failure. Am J Cardiol 1997;80:61-64.

  23. Seino Y, Momomura S, Takano T et al. Multicenter, double bind study of intravenous milrinone for patients with acute heart failure in Japan. Crit Care Med 1996;24(9);1490-97.

  24. Gilbert EM, Hershberger RE, Wiechmann RJ et al. Pharmacologic and hemodynamic effects of combined betaagonist stimulation and phosphodiesterase inhibition in the failing human heart. Chest 1995;108:1524-32.

  25. Effect of pimobendan on excercise capacity in patientes with heart failure: main results from the pimobendan in congestive heart failure (PICO) trial. Heart 1996;76:223-231.

  26. Califf RM, Bengston JR. Choque cardiogénico. Mundo Médico 1994;22(247):17-24.

  27. Philbin EF, Cotto M, Rocco TA, Jenkins PL. Association between diuretic use, clinical response, and death in acute heart failure. Am J Cardiol 1997;80(15):519-22.

  28. Dormans TP, Pickkers P, Russel FG, Smits P. Vascular effects of loop diuretics. Cardiovasculae Research 1996;32:988-97.

  29. Fleming F, Bohn D, Edwards H et al. Renal replacement therapy after repair of congenital heart disease in children. J Thorac Cardiovasc Surg 1995;109(2):322-31.

  30. Levy B, Bollaert PE, Charpentier C et al. Comparison of norepinephrine and dobutamine to epinephrine for hemodynamics, lactate metabolism, and gastric tonometric variables in septic shock: a prospective, randomized study. Intensive Care Med 1997; 23:282-287.

  31. Levy B, Bollaert PE, Lucchelli JP. Dobutamine improves the adecuacy of gastric mucosal perfusion in epinephrine treated septic shock. Crit Care Med 1997;25(10):1649-54.

  32. Lherm T, Troché G, Rossignol M et al. Renal effects of low dose dopamine in patients with sepsis syndrom or septic shock treated with cathecolamines. Intensive Care Med 1996;22:213-19.

  33. Meier-Hellman A, Specht M, Hanneman L et al. Splachnic blood flow is greater in septic shock treated with norepinephrine than in severe sepsis. Intensive Care Med 1996;22:1354-59.

  34. Richer M, Robert S, Lebel M. Renal hemodynamics during epinephrine and low dose dopamine infusions in man. Crit Care Med 1996;24(7):1150-56.

  35. Bollaert PE, Bauer P, Audibert G et al. Effects of epinephrine on hemodynamics and oxygen metabolism in dopamine- resistant septic shock. Chest 1990;98:949-53.

  36. Meier-Hellman A, Reinhart K, Bredle DL et al. Epinephrine impairs splachnic perfusion in septic shock. Crit Care Med 1997;25(3):399-404.

  37. Ruokonen E, Uusaro A, Alhava E, Takala J. The effect of dobutamine infusion on splachnic blood flow and oxygen transport in patients with acute pancreatitis. Intensive Care Med 1997;23:732-37.

  38. Allen E, Pettigrew A, Frank D et al. Alterations in dopamine clearence and catechol-Omethyltransfersase activity by dopamine infusions in children. Crit Care Med 1997;25(1):181-89.

  39. Greenberg B, Quinones MA, Koilpillal C et al. Effects of long term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction: results of the SOLVD echocardiography study. Circulation 1995;91:2573-81.

  40. Po-Yin Ch, Barrington KJ. Renal dopamine receptors:mechanisms of action and developmental aspects. Cardiovascular Res 1996;31:2-6.

  41. Alon US, Scagliotti D, Garola RE. Nephrocalcinosis and nephrolithiasis in infants with congestive heart failure treated with furosemide. J Pediatr 1994;125(1):149-51.

  42. Van Veldhuisen DJ, de Graeff PA, Remme WJ et al. Value of digoxin in Heart Failure and sinus rythm: new features of an old drug? JACC 1996;28(4):813-19.

  43. Mendelsohn AM, Johnson CE, Brown CE et al. Hemodynamic and clinical effects of oral levodopa in children with congestive heart failure. JACC 1997;30(1):237-42.

  44. Escobar CG, Cabrera AC. Vanguardia en el manejo de patologías cardiovasculares: Inhibidores del receptor para Angiotensina II (AT-1). Fisiología, farmacocinética y su comparación con tratamientos convencionales. Revista Médica La Salle 1998;19(2):59-67.

  45. Shaddy RE, Olsen SL, Bristow MR. Efficacy and safety of metoprolol in the treatment of doxorrubicin-induced cardiomyopathy in pediatric patients. Am Heart J 1995;129:197-9.

  46. Shaddy RE. Betablocker therapy in young children with congestive heart failure under consideration for heart transplantation. Am Heart J 1998 136(1):4-5.

  47. Nicholls MG. Hypertension, hypertrophy, heart failure. Heart 1996;76 (Suppl 3):92-97.

  48. Hillis GS, Al Mohammed A, Wood M, Jennings KP. Changing patterns of investigation and treatment of cardiac failure in hospital. Heart 1996;76:427-29.

  49. Monson JP, Besser GM. The potential for growth hormone in the management of heart failure. Heart 1997;77:1-2.

  50. Lampt M, Lorber A, Vilkas DL et al. GH dependence and GH withdrawal syndrome in GH treatment of short normal children: evidence from growth and cardiac output. European Journal of Endocrinolgy 1998;138(4):401-7.

  51. Yang R, Bunting S, Gullet N et al. Growth hormone improves cardiac performance in experimental heart failure. Circulation 1995;92(2):263-267.

  52. Nielsen-Kudsk JE, Boesgaard S, Aldershvile J. K+ channel opening: a new drug principle in cardiovascular medicine. Heart 1996;76:109-16.




2020     |     www.medigraphic.com